TEL AVIV, Israel, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug, MG01CI (Sustained-Release Metadoxine), to treat cognitive dysfunction, announced today positive findings from a pre-clinical study with a mouse model of Fragile X Syndrome. The study showed significant improvement in cognitive and social functioning following treatment with MG01CI in a valid animal model of Fragile X Syndrome (FMR1 knock-out mouse model).
Help employers find you! Check out all the jobs and post your resume.
